Intermune's orphan Esbriet falls foul of Germany's benefit assessment
This article was originally published in Scrip
Executive Summary
Intermune's orphan drug Esbriet (pirfenidone) offers no quantifiable additional benefit for treating idiopathic pulmonary fibrosis (IPF) over comparators, according to IQWiG, Germany's Institute for Quality and Efficiency in Healthcare. The decision comes after it conducted the first ever benefit assessment of an orphan drug under new procedures introduced by the healthcare reform act, the AMNOG.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.